Professional Documents
Culture Documents
Resistance
Dr Klara Tisocki
Coordinator for Essential Medicines and Health Technologies,
WHO Regional Office for the Western Pacific
Overview
The Global Threat of Antimicrobial
Resistance
(Photo by CDC)
Gonorrhoe
a
Wound
infections
Modern
medicine
Organ
Transplants
Preterm
babies
Urinary
tract
infections
Complicate
d deliveries
Pneumonia
Antibiotics
Maternal and
child health
Blood
infections
Basic
health care
Thailand
United States
population 500m
population 70m
population 300m
>38,000 deaths
>23,000 deaths
>2.0m illnesses
Global information is insufficient to show complete disease burden impacts and costs
Dr Margaret Chan
(WHO)
Evolution
Premature resistance due to inappropriate use
Economy
No new medicine due to inadequate market incentives
Behavioural factors
o patients poor adherence, self-medication, cultural
preferences/beliefs
o unclear diagnosis, financial incentives, industry promotion
Medicines factors
o long drug half-life, cross-resistance between classes, treatment
length and complexity, monotherapy, lack of effective new
combinations
11
Ensure Access
o preserve the ability to prevent and treat infections
Sustainability
o all countries to have a National Plan by 2017
Incremental targets for implementation
o different states for different countries
Optimize the
use of
antimicrobial
medicines in
human and
animal health
Reduce infections
through effective
sanitation,
hygiene and
infection
prevention
National cross-sectoral
commitments to implement
national plans on AMR
Sustained financing of
investments for new
products (diagnostics,
medicines)
Globally, regionally
coordinated efforts to
change attitudes,
behaviours, health system
practices to tackle AMR
Antimicrobial Resistance
Awareness
and
Advocacy
UHC
UHC
One Health
UHC
One Health
SDGs
UHC
One Health
SDGs
GOVERNANCE OF AMR as a development agenda
UHC
One Health
SDGs
GOVERNANCE OF AMR as a development agenda
Nationa
l
National Action
Plan on AMR
Region
al
Harmonization of
surveillance and
regulations
Global
Enhance R&D
(new antibiotics and
diagnostics)
Members: Dept of Trade and Industry, Dept of Interior and Local Govt, Dept of
Science and Technology
Key Stakeholders
Civil Societies and Patient Organizations: Med Transparency Alliance, Phil Assoc
of Patient Organizations
FSC/CAO
MHLW
MAFF
MEXT
MOFA
MOE
Food Safety
Commission,
Cabinet Office
Ministry of Health,
Labour and
Welfare
Ministry of
Agriculture,
Forestry and
Fisheries
Ministry of Education,
Culture, Sports,
Science and
Technology
Ministry of
Foreign Affairs
Ministry of the
Environment
NIID
NCGM
PMDA
AMED
NVAL
National
Institute of
Infectious
Diseases
National
Center for
Global
Health and
Medicine
Pharmaceutic
al and Medical
Devices
Agency
Japan
Agency for
Medical
Research
and
National
Veterinary
Assay
Laboratory
NARO
FAMIC
National
Food and
Agriculture Agricultural
and Food
Materials
25
Research
Inspection
Organization
Center
FRA
JICA
Fisheries
Research
Agency
Japan
International
Cooperation
Agency
Republic of Korea
Samoa
Cook Island
Progress on AMR
2. Support antimicrobial stewardship training
Philippines
Lao Peoples Democratic Republic
Mongolia
Ministerial Communique
Control of Antimicrobial Resistance requires coordinated
strategies involving multiple sectors:
o
o
o
o
Human health
Animal health
Agriculture, food safety, food production
Environmental protection sectors
Asia Pacific
Summary
The antimicrobial resistance threat is already affecting
all countries.
Every day people die from infections that do not
respond anymore to antibiotics.
Thank you
Dr Klara Tisocki
Coordinator Essential Medicines and Health Technologies
WHO Western Pacific Regional Office
tisockik@wpro.who.int
www.wpro.who.int/topics/drug_resistance/en/
36